Crown Bioscience Inc., of Santa Clara, Calif., said it expanded its cardiovascular and metabolic disease (CVMD) research in New Iberia, Louisiana by investing in facilities at the University of Louisiana at Lafayette's New Iberia Research Center, the largest national primate research center in the U.S. Read More
Mirati Therapeutics Inc., of San Diego, said it closed its underwritten public offering of 5 million shares of its common stock at $5.60 each. Read More
SAN FRANCISCO – For the first time since emerging from stealth mode last year, 2015 startup Kiniksa Pharmaceuticals disclosed its $80 million series A round and introduced the first compound in its pipeline, an antibody targeting inflammation and fibrosis. Read More
Researchers at Tokyo's Keio University School of Medicine have developed the first in vitro cochlear cell model using patient-derived disease-specific human induced pluripotent stem cells (hiPSCs), which allows study of the pathogenesis of congenital deafness and may lead to its treatment. Read More
Curevac AG's mRNA-based prostate cancer vaccine CV9104, long its lead candidate, failed to meet the primary endpoint of improving overall survival during a phase IIb trial. Progression-free survival in treated patients was similar to those in the placebo arm. Read More
Consultants at Avalere Health came up with an array of trends likely to shake, rattle, and roll the industry in the coming year, as President-elect Donald Trump takes office and worries of a crackdown on drug pricing recede, but don't go away entirely. Read More
Shionogi & Co. Ltd., of Osaka, Japan, said cefiderocol (S-649266), a siderophore cephalosporin in late-stage development, met the FDA pre-specified primary endpoint for noninferiority vs. imipenem/cilastatin (IPM/CS) in patients with serious complicated urinary tract infection (cUTI) with gram-negative bacteria. Cefiderocol was superior to IPM/CS at test of cure (TOC). Read More
